Yorkville Advisors Global LP Buys New Position in OraSure Technologies, Inc. $OSUR

Yorkville Advisors Global LP purchased a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 635,000 shares of the medical instruments supplier’s stock, valued at approximately $1,905,000. OraSure Technologies makes up approximately 1.2% of Yorkville Advisors Global LP’s portfolio, making the stock its 13th largest position.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OSUR. Quadrature Capital Ltd acquired a new stake in OraSure Technologies in the fourth quarter valued at approximately $28,000. Prudential Financial Inc. acquired a new position in shares of OraSure Technologies during the second quarter worth $31,000. Diversify Wealth Management LLC acquired a new position in shares of OraSure Technologies during the first quarter worth $36,000. Amundi purchased a new position in shares of OraSure Technologies in the first quarter valued at $47,000. Finally, SG Americas Securities LLC boosted its stake in shares of OraSure Technologies by 77.7% in the fourth quarter. SG Americas Securities LLC now owns 19,748 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 8,632 shares during the period. Hedge funds and other institutional investors own 93.50% of the company’s stock.

OraSure Technologies Stock Performance

NASDAQ:OSUR opened at $3.79 on Thursday. The stock has a market cap of $260.94 million, a price-to-earnings ratio of -3.64 and a beta of 1.01. OraSure Technologies, Inc. has a one year low of $2.08 and a one year high of $4.58. The business’s 50-day simple moving average is $4.04 and its 200 day simple moving average is $3.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, OraSure Technologies has a consensus rating of “Reduce” and an average target price of $3.00.

Insider Transactions at OraSure Technologies

In other OraSure Technologies news, Director Steven Kyle Boyd bought 25,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were bought at an average cost of $2.99 per share, with a total value of $74,750.00. Following the transaction, the director directly owned 113,462 shares in the company, valued at approximately $339,251.38. This trade represents a 28.26% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.70% of the stock is owned by corporate insiders.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.